Trial Profile
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sovleplenib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 08 Oct 2018 Planned number of patients changed from 92 to 217.
- 08 Oct 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 08 Oct 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.